IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.
Melanoma cells express ganglioside antigens GM3, GD3, GM2, and GD2 on their surface. This study examined whether immunization with a melanoma cell vaccine induced anti-ganglioside antibody responses in melanoma patients and whether these responses were correlated with survival. Sixty-six patients who had received melanoma cell vaccine immunotherapy after surgical removal of regional metastatic melanoma were identified. Cryopreserved serum samples from these patients were used in an enzyme-linked immunsorbent assay to determine the IgM antibody levels to GM2, GD2, GM3, and GD3 prior to melanoma cell vaccine treatment and 4 wk after the first melanoma cell vaccine immunization. All antibody levels significantly increased by week 4 (p < 0.001 for all four antibodies) and all increases were significantly associated with survival (anti-GD2, p < 0.001; anti-GM2, p = 0.001; anti-GD3, p < 0.001; anti-GM3, p < 0.001). Anti-tumor activity of these antibodies was proved using five representative antibody-positive sera in a complement-dependent cytotoxicity assay with cultured melanoma cell lines. These studies suggest that GM2, GD2, GM2, and GD3 expressed by melanoma cells can induce specific IgM antibodies and that high levels of these antibodies might have a beneficial impact on survival.
Takahashi
T
T
Department of Biotechnology Sciences, John Wayne Cancer Institute, Santa Monica, California 90404, USA.
Johnson
T D
TD
Nishinaka
Y
Y
Morton
D L
DL
Irie
R F
RF
D000888:Antibodies, Anti-Idiotypic / Q000097:blood / Q000276:immunology*; D000917:Antibody Formation; D019496:Cancer Vaccines; D003602:Cytotoxicity, Immunologic; D005678:G(M2) Ganglioside / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D008545:Melanoma / Q000276:immunology* / Q000401:mortality; D015996:Survival Rate